EDN3/EDNRB Waardenburg-Shah

Genetic MONDO:0019518 Pathograph 7 Waardenburg Syndrome Hirschsprung Disease Neurocristopathy

EDN3/EDNRB-related Waardenburg-Shah syndrome is a neural crest signaling-axis disorder in which reduced endothelin-3 ligand or endothelin receptor type B signaling impairs melanoblast and enteric neural crest development. Biallelic loss-of-function in EDNRB or EDN3 causes Waardenburg syndrome type 4A or 4B with sensorineural hearing loss, pigmentary abnormalities, and Hirschsprung disease. Heterozygous variants can contribute to incompletely penetrant disease or Hirschsprung/WS2-like susceptibility, especially for EDNRB, so this entry models the ligand-receptor axis with gene-specific inheritance and evidence notes.

Ask OpenScientist

Ask a research question about EDN3/EDNRB Waardenburg-Shah. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

3
Inheritance
5
Pathophys.
3
Phenotypes
7
Pathograph
2
Genes
2
Subtypes
1
Deep Research
👪

Inheritance

3
Autosomal recessive inheritance HP:0000007
Biallelic EDNRB or EDN3 loss is the best-supported mechanism for WS4A/WS4B with Hirschsprung disease and auditory-pigmentary features.
Autosomal recessive inheritance
Autosomal dominant inheritance with incomplete penetrance HP:0000006
Heterozygous EDNRB, and more weakly EDN3, variants can contribute to incompletely penetrant WS/Hirschsprung susceptibility. ClinGen classifies these AD gene-disease assertions as Limited.
Autosomal dominant inheritance Penetrance: INCOMPLETE
Semidominant endothelin-axis dosage HP:0032113
The ligand-receptor axis is modeled as dosage-sensitive because biallelic defects cause classic WS4, while heterozygous variants can produce incomplete or susceptibility phenotypes.
Semidominant inheritance
◆

Subtypes

2
Waardenburg Syndrome Type 4A MONDO:0010192
EDNRB-related Waardenburg-Shah syndrome. The best-supported disease model is autosomal recessive loss of receptor function, with limited evidence for autosomal dominant or incompletely penetrant heterozygous presentations.
Waardenburg Syndrome Type 4B MONDO:0013201
EDN3-related Waardenburg-Shah syndrome. The best-supported disease model is autosomal recessive ligand deficiency, with limited evidence for heterozygous contribution.
⚙

Pathophysiology

5
EDN3 ligand and EDNRB receptor signaling deficiency
Pathogenic variants reduce endothelin-3 ligand availability, endothelin receptor type B function, or receptor-mediated signaling in neural crest-derived melanoblast and enteric precursor populations.
melanoblast link enteric neuron link
EDN3 link EDNRB link
Downstream
Terminal migration defect of melanoblast and enteric precursors Loss of endothelin signaling impairs terminal migration of melanoblast and enteric neural crest precursors.
Show evidence (2 references)
PMID:11434563 SUPPORT Other
"Mutations in the genes encoding the endothelin type-B receptor (EDNRB) and its physiological ligand endothelin 3 (EDN3) are now known to account for the majority of HSCR II patients."
Establishes the ligand-receptor gene pair as the endothelin-axis cause of WS4/HSCR II phenotypes.
PMID:8630502 SUPPORT Human Clinical
"EDN3 thus becomes the third known gene (after RET and EDNRB) predisposing to HSCR, supporting the view that the endothelin-signaling pathways play a major role in the development of neural crests."
Links EDN3 to the same neural crest endothelin pathway as EDNRB.
Terminal migration defect of melanoblast and enteric precursors
EDNRB-mediated signaling is required during a critical embryonic window for terminal migration of melanoblast and enteric neuron precursors, rather than for their initial specification from the neural crest.
melanoblast link enteric neuron link
neural crest cell migration link ↓ DECREASED
Downstream
Stria vascularis and cutaneous melanocyte deficiency Failed melanoblast migration reduces melanocytes in pigmentary and auditory tissues.
Enteric ganglion cell deficiency Failed enteric precursor migration produces aganglionosis.
Show evidence (1 reference)
PMID:12812796 SUPPORT Model Organism
"EDNRB signaling is exclusively required between E10.5 and E12.5 during the migratory phase of melanoblast and enteric neuroblast development."
Mechanistically localizes EDNRB signaling to the migration phase of the affected neural crest-derived precursors.
Stria vascularis and cutaneous melanocyte deficiency
Melanocyte deficiency in the epidermis, hair, iris, and cochlear stria vascularis produces the pigmentary and sensorineural hearing components of Waardenburg-Shah syndrome.
melanocyte link
pigmentation link ↓ DECREASED
stria vascularis link
Show evidence (1 reference)
PMID:16650841 SUPPORT Model Organism
"double mutants present with a severe increase in white spotting, absence of melanocytes within the inner ear, and in the stria vascularis in particular, and more severe ENS defects."
Supports combined SOX10/endothelin-axis effects on pigmentation, cochlear melanocytes, and ENS development.
Enteric ganglion cell deficiency
Reduced enteric neural crest colonization leaves distal bowel regions aganglionic, producing Hirschsprung disease.
enteric neuron link ∅ ABSENT
enteric nervous system development link ⚠ ABNORMAL
Show evidence (2 references)
PMID:8001158 SUPPORT Human Clinical
"Hirschsprung's disease (HSCR) is characterized by an absence of enteric ganglia"
Defines the enteric ganglion deficiency phenotype connected to EDNRB in the same report.
PMID:8630503 SUPPORT Human Clinical
"Here, we describe a mutation of the human gene for endothelin 3 (EDN3), homozygously present in a patient with a combined Waardenburg syndrome type 2 (WS2) and HSCR phenotype (Shah-Waardenburg syndrome)."
Establishes EDN3 mutation in combined Waardenburg and Hirschsprung disease.
Heterozygous EDNRB susceptibility
Heterozygous EDNRB variants can cause or contribute to WS2-like or WS4-like phenotypes with incomplete penetrance. This arm is modeled as a limited, dosage-sensitive susceptibility mechanism rather than the canonical AR WS4A mechanism.
EDNRB link
Show evidence (2 references)
PMID:28236341 SUPPORT Human Clinical
"molecular segregation investigations unraveled a dominant mode of inheritance with incomplete penetrance."
Supports incompletely penetrant heterozygous EDNRB disease contribution.
PMID:28236341 SUPPORT Human Clinical
"We now estimate EDNRB mutations to be responsible for 5%-6% of WS2."
Quantifies the reported contribution of heterozygous EDNRB variants to WS2 in this cohort study.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for EDN3/EDNRB Waardenburg-Shah Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

3
Ear 1
Sensorineural hearing impairment FREQUENT Sensorineural hearing impairment (HP:0000407)
Show evidence (1 reference)
CGGV:assertion_d7abbd45-7915-437b-849b-dea876bfc2f5-2023-06-27T160000.000Z SUPPORT Other
"This condition is associated with sensorineural hearing loss; atypical pigmentation of the hair, skin, and eyes; and Hirschsprung’s disease (aganglionic megacolon)."
ClinGen summarizes sensorineural hearing loss as part of the EDNRB WS4A phenotype.
Other 2
Aganglionic megacolon VERY_FREQUENT Aganglionic megacolon (HP:0002251)
Show evidence (1 reference)
PMID:11434563 SUPPORT Other
"WS type 4 (WS4), or Shah-Waardenburg syndrome, is also known as Hirschsprung disease Type II (HSCR II) and is characterized by an absence of epidermal melanocytes and enteric ganglia."
Defines WS4 as combined melanocyte and enteric ganglion deficiency.
Pigmentary abnormality VERY_FREQUENT
Show evidence (1 reference)
PMID:11434563 SUPPORT Other
"characterized by an absence of epidermal melanocytes and enteric ganglia."
Links EDN3/EDNRB-associated WS4 to epidermal melanocyte deficiency.
🧬

Genetic Associations

2
EDNRB (Causative and incompletely penetrant susceptibility)
Show evidence (1 reference)
PMID:8001158 SUPPORT Human Clinical
"We recently mapped a recessive susceptibility locus (HSCR2) to human chromosome 13q22, which we now demonstrate to be the endothelin-B receptor gene (EDNRB)."
Original EDNRB human disease mapping in Hirschsprung disease.
EDN3 (Causative)
Show evidence (1 reference)
PMID:8630502 SUPPORT Human Clinical
"Here, we report a homozygous substitution/deletion mutation of the EDN3 gene in a WS-HSCR patient."
Establishes homozygous EDN3 mutation in Waardenburg-Hirschsprung disease.
{ }

Source YAML

click to show 
name: EDN3/EDNRB Waardenburg-Shah
creation_date: '2026-05-28T00:00:00Z'
description: >-
  EDN3/EDNRB-related Waardenburg-Shah syndrome is a neural crest signaling-axis
  disorder in which reduced endothelin-3 ligand or endothelin receptor type B
  signaling impairs melanoblast and enteric neural crest development. Biallelic
  loss-of-function in EDNRB or EDN3 causes Waardenburg syndrome type 4A or 4B
  with sensorineural hearing loss, pigmentary abnormalities, and Hirschsprung
  disease. Heterozygous variants can contribute to incompletely penetrant
  disease or Hirschsprung/WS2-like susceptibility, especially for EDNRB, so this
  entry models the ligand-receptor axis with gene-specific inheritance and
  evidence notes.
category: Genetic
parents:
- Waardenburg Syndrome
- Hirschsprung Disease
- Neurocristopathy
disease_term:
  preferred_term: Waardenburg-Shah syndrome
  term:
    id: MONDO:0019518
    label: Waardenburg-Shah syndrome
tracked_issues:
- url: https://github.com/monarch-initiative/dismech/issues/3309
  title: Curate Waardenburg syndrome as gene-axis mechanism spectra
  tracked_issue_role: curation_followup
  tracked_issue_status: OPEN
  notes: >-
    Issue 3309 requested EDN3/EDNRB ligand-receptor axis modeling for
    Waardenburg-Shah syndrome.
external_assertions:
- name: ClinGen EDNRB autosomal recessive Waardenburg syndrome type 4A validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_d7abbd45-7915-437b-849b-dea876bfc2f5-2023-06-27T160000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_d7abbd45-7915-437b-849b-dea876bfc2f5-2023-06-27T160000.000Z
  description: >-
    ClinGen assertion classifying EDNRB and autosomal recessive Waardenburg
    syndrome type 4A as Moderate.
  evidence:
  - reference: CGGV:assertion_d7abbd45-7915-437b-849b-dea876bfc2f5-2023-06-27T160000.000Z
    reference_title: EDNRB / Waardenburg syndrome type 4A (Moderate)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The mechanism of pathogenicity appears to be loss-of-function.
    explanation: >-
      Supports EDNRB loss of function as a curated AR WS4A mechanism.
- name: ClinGen EDNRB autosomal dominant Waardenburg syndrome type 4A validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_73ee9727-60c1-40fd-830f-08c2b513d2ee-2018-05-08T160000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_73ee9727-60c1-40fd-830f-08c2b513d2ee-2018-05-08T160000.000Z
  description: >-
    ClinGen assertion classifying EDNRB and autosomal dominant Waardenburg
    syndrome type 4A as Limited.
  evidence:
  - reference: CGGV:assertion_73ee9727-60c1-40fd-830f-08c2b513d2ee-2018-05-08T160000.000Z
    reference_title: EDNRB / Waardenburg syndrome type 4A (Limited)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In summary, there is limited evidence to support this gene-disease association.
    explanation: >-
      Records the weaker autosomal dominant EDNRB evidence and keeps
      heterozygous disease modeling limited/incompletely penetrant.
- name: ClinGen EDN3 autosomal recessive Waardenburg syndrome type 4B validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_7f88c34c-a093-4fc8-b84a-49c7d2dd327f-2023-06-29T160000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_7f88c34c-a093-4fc8-b84a-49c7d2dd327f-2023-06-29T160000.000Z
  description: >-
    ClinGen assertion classifying EDN3 and autosomal recessive Waardenburg
    syndrome type 4B as Moderate.
  evidence:
  - reference: CGGV:assertion_7f88c34c-a093-4fc8-b84a-49c7d2dd327f-2023-06-29T160000.000Z
    reference_title: EDN3 / Waardenburg syndrome type 4B (Moderate)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In summary, there is moderate evidence to support this gene-disease association.
    explanation: >-
      Records the current structured AR EDN3/WS4B validity assertion.
- name: ClinGen EDN3 autosomal dominant Waardenburg syndrome type 4B validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_04e39ada-cd77-43f0-98f3-7b4a37668a96-2018-05-08T160000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_04e39ada-cd77-43f0-98f3-7b4a37668a96-2018-05-08T160000.000Z
  description: >-
    ClinGen assertion classifying EDN3 and autosomal dominant Waardenburg
    syndrome type 4B as Limited.
  evidence:
  - reference: CGGV:assertion_04e39ada-cd77-43f0-98f3-7b4a37668a96-2018-05-08T160000.000Z
    reference_title: EDN3 / Waardenburg syndrome type 4B (Limited)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In summary, there is limited evidence to support this gene-disease association.
    explanation: >-
      Records the weaker autosomal dominant EDN3 evidence as a limited
      heterozygous/dosage caveat rather than the core mechanism.
has_subtypes:
- name: Waardenburg Syndrome Type 4A
  display_name: Waardenburg Syndrome Type 4A
  subtype_term:
    preferred_term: Waardenburg syndrome type 4A
    term:
      id: MONDO:0010192
      label: Waardenburg syndrome type 4A
  description: >-
    EDNRB-related Waardenburg-Shah syndrome. The best-supported disease model is
    autosomal recessive loss of receptor function, with limited evidence for
    autosomal dominant or incompletely penetrant heterozygous presentations.
- name: Waardenburg Syndrome Type 4B
  display_name: Waardenburg Syndrome Type 4B
  subtype_term:
    preferred_term: Waardenburg syndrome type 4B
    term:
      id: MONDO:0013201
      label: Waardenburg syndrome type 4B
  description: >-
    EDN3-related Waardenburg-Shah syndrome. The best-supported disease model is
    autosomal recessive ligand deficiency, with limited evidence for
    heterozygous contribution.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Biallelic EDNRB or EDN3 loss is the best-supported mechanism for WS4A/WS4B
    with Hirschsprung disease and auditory-pigmentary features.
- name: Autosomal dominant inheritance with incomplete penetrance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: INCOMPLETE
  description: >-
    Heterozygous EDNRB, and more weakly EDN3, variants can contribute to
    incompletely penetrant WS/Hirschsprung susceptibility. ClinGen classifies
    these AD gene-disease assertions as Limited.
- name: Semidominant endothelin-axis dosage
  inheritance_term:
    preferred_term: Semidominant inheritance
    term:
      id: HP:0032113
      label: Semidominant inheritance
  description: >-
    The ligand-receptor axis is modeled as dosage-sensitive because biallelic
    defects cause classic WS4, while heterozygous variants can produce
    incomplete or susceptibility phenotypes.
phenotypes:
- category: Gastrointestinal
  name: Aganglionic megacolon
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Aganglionic megacolon
    term:
      id: HP:0002251
      label: Aganglionic megacolon
  description: >-
    Hirschsprung disease results from failed enteric neural crest development
    and is the defining enteric component of Waardenburg-Shah syndrome.
  evidence:
  - reference: PMID:11434563
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      WS type 4 (WS4), or Shah-Waardenburg syndrome, is also known as Hirschsprung disease Type II (HSCR II) and is characterized by an absence of epidermal melanocytes and enteric ganglia.
    explanation: >-
      Defines WS4 as combined melanocyte and enteric ganglion deficiency.
- category: Audiological
  name: Sensorineural hearing impairment
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  description: >-
    Sensorineural hearing loss is part of the Waardenburg component of the
    EDN3/EDNRB axis phenotype.
  evidence:
  - reference: CGGV:assertion_d7abbd45-7915-437b-849b-dea876bfc2f5-2023-06-27T160000.000Z
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This condition is associated with sensorineural hearing loss; atypical pigmentation of the hair, skin, and eyes; and Hirschsprung’s disease (aganglionic megacolon).
    explanation: >-
      ClinGen summarizes sensorineural hearing loss as part of the EDNRB WS4A
      phenotype.
- category: Dermatologic
  name: Pigmentary abnormality
  frequency: VERY_FREQUENT
  description: >-
    Hypopigmented skin or hair patches and ocular pigmentary findings reflect
    melanoblast and melanocyte developmental failure.
  evidence:
  - reference: PMID:11434563
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      characterized by an absence of epidermal melanocytes and enteric ganglia.
    explanation: >-
      Links EDN3/EDNRB-associated WS4 to epidermal melanocyte deficiency.
pathophysiology:
- name: EDN3 ligand and EDNRB receptor signaling deficiency
  description: >-
    Pathogenic variants reduce endothelin-3 ligand availability, endothelin
    receptor type B function, or receptor-mediated signaling in neural
    crest-derived melanoblast and enteric precursor populations.
  genes:
  - preferred_term: EDN3
    term:
      id: hgnc:3178
      label: EDN3
  - preferred_term: EDNRB
    term:
      id: hgnc:3180
      label: EDNRB
  cell_types:
  - preferred_term: melanoblast
    term:
      id: CL:0000541
      label: melanoblast
  - preferred_term: enteric neuron
    term:
      id: CL:0007011
      label: enteric neuron
  evidence:
  - reference: PMID:11434563
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mutations in the genes encoding the endothelin type-B receptor (EDNRB) and its physiological ligand endothelin 3 (EDN3) are now known to account for the majority of HSCR II patients.
    explanation: >-
      Establishes the ligand-receptor gene pair as the endothelin-axis cause of
      WS4/HSCR II phenotypes.
  - reference: PMID:8630502
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EDN3 thus becomes the third known gene (after RET and EDNRB) predisposing to HSCR, supporting the view that the endothelin-signaling pathways play a major role in the development of neural crests.
    explanation: >-
      Links EDN3 to the same neural crest endothelin pathway as EDNRB.
  downstream:
  - target: Terminal migration defect of melanoblast and enteric precursors
    description: >-
      Loss of endothelin signaling impairs terminal migration of melanoblast and
      enteric neural crest precursors.
- name: Terminal migration defect of melanoblast and enteric precursors
  conforms_to: "neural_crest_melanocyte_deficiency#Melanoblast Migration and Survival Defect"
  description: >-
    EDNRB-mediated signaling is required during a critical embryonic window for
    terminal migration of melanoblast and enteric neuron precursors, rather than
    for their initial specification from the neural crest.
  cell_types:
  - preferred_term: melanoblast
    term:
      id: CL:0000541
      label: melanoblast
  - preferred_term: enteric neuron
    term:
      id: CL:0007011
      label: enteric neuron
  biological_processes:
  - preferred_term: neural crest cell migration
    term:
      id: GO:0001755
      label: neural crest cell migration
    modifier: DECREASED
  evidence:
  - reference: PMID:12812796
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      EDNRB signaling is exclusively required between E10.5 and E12.5 during the migratory phase of melanoblast and enteric neuroblast development.
    explanation: >-
      Mechanistically localizes EDNRB signaling to the migration phase of the
      affected neural crest-derived precursors.
  downstream:
  - target: Stria vascularis and cutaneous melanocyte deficiency
    description: >-
      Failed melanoblast migration reduces melanocytes in pigmentary and
      auditory tissues.
  - target: Enteric ganglion cell deficiency
    description: >-
      Failed enteric precursor migration produces aganglionosis.
- name: Stria vascularis and cutaneous melanocyte deficiency
  conforms_to: "neural_crest_melanocyte_deficiency#Stria Vascularis Melanocyte Deficiency"
  description: >-
    Melanocyte deficiency in the epidermis, hair, iris, and cochlear stria
    vascularis produces the pigmentary and sensorineural hearing components of
    Waardenburg-Shah syndrome.
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  locations:
  - preferred_term: stria vascularis
    term:
      id: UBERON:0002282
      label: stria vascularis of cochlear duct
  biological_processes:
  - preferred_term: pigmentation
    term:
      id: GO:0043473
      label: pigmentation
    modifier: DECREASED
  evidence:
  - reference: PMID:16650841
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      double mutants present with a severe increase in white spotting, absence of melanocytes within the inner ear, and in the stria vascularis in particular, and more severe ENS defects.
    explanation: >-
      Supports combined SOX10/endothelin-axis effects on pigmentation, cochlear
      melanocytes, and ENS development.
- name: Enteric ganglion cell deficiency
  description: >-
    Reduced enteric neural crest colonization leaves distal bowel regions
    aganglionic, producing Hirschsprung disease.
  cell_types:
  - preferred_term: enteric neuron
    modifier: ABSENT
    term:
      id: CL:0007011
      label: enteric neuron
  biological_processes:
  - preferred_term: enteric nervous system development
    term:
      id: GO:0048484
      label: enteric nervous system development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:8001158
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hirschsprung's disease (HSCR) is characterized by an absence of enteric ganglia
    explanation: >-
      Defines the enteric ganglion deficiency phenotype connected to EDNRB in
      the same report.
  - reference: PMID:8630503
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we describe a mutation of the human gene for endothelin 3 (EDN3), homozygously present in a patient with a combined Waardenburg syndrome type 2 (WS2) and HSCR phenotype (Shah-Waardenburg syndrome).
    explanation: >-
      Establishes EDN3 mutation in combined Waardenburg and Hirschsprung
      disease.
- name: Heterozygous EDNRB susceptibility
  description: >-
    Heterozygous EDNRB variants can cause or contribute to WS2-like or WS4-like
    phenotypes with incomplete penetrance. This arm is modeled as a limited,
    dosage-sensitive susceptibility mechanism rather than the canonical AR WS4A
    mechanism.
  genes:
  - preferred_term: EDNRB
    term:
      id: hgnc:3180
      label: EDNRB
  evidence:
  - reference: PMID:28236341
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      molecular segregation investigations unraveled a dominant mode of inheritance with incomplete penetrance.
    explanation: >-
      Supports incompletely penetrant heterozygous EDNRB disease contribution.
  - reference: PMID:28236341
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We now estimate EDNRB mutations to be responsible for 5%-6% of WS2.
    explanation: >-
      Quantifies the reported contribution of heterozygous EDNRB variants to
      WS2 in this cohort study.
genetic:
- name: EDNRB
  gene_term:
    preferred_term: EDNRB
    term:
      id: hgnc:3180
      label: EDNRB
  association: Causative and incompletely penetrant susceptibility
  subtype: Waardenburg Syndrome Type 4A
  features: >-
    Biallelic EDNRB loss is the core WS4A mechanism. Heterozygous EDNRB variants
    have limited but notable evidence for incompletely penetrant WS/HSCR
    susceptibility.
  evidence:
  - reference: PMID:8001158
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We recently mapped a recessive susceptibility locus (HSCR2) to human chromosome 13q22, which we now demonstrate to be the endothelin-B receptor gene (EDNRB).
    explanation: >-
      Original EDNRB human disease mapping in Hirschsprung disease.
- name: EDN3
  gene_term:
    preferred_term: EDN3
    term:
      id: hgnc:3178
      label: EDN3
  association: Causative
  subtype: Waardenburg Syndrome Type 4B
  features: >-
    Biallelic EDN3 ligand defects cause WS4B/Shah-Waardenburg syndrome.
    Heterozygous EDN3 evidence remains limited and is treated as a secondary
    dosage caveat.
  evidence:
  - reference: PMID:8630502
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report a homozygous substitution/deletion mutation of the EDN3 gene in a WS-HSCR patient.
    explanation: >-
      Establishes homozygous EDN3 mutation in Waardenburg-Hirschsprung disease.
notes: >-
  This entry intentionally models EDN3 and EDNRB together as a ligand-receptor
  axis while preserving gene-specific subtypes and ClinGen AD/AR assertions.
  Isolated Hirschsprung disease and non-syndromic EDNRB/EDN3 susceptibility are
  related but not the main disease scope here.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 2026-05-28T12:28:40.461410

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: EDN3/EDNRB Waardenburg-Shah
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on EDN3/EDNRB Waardenburg-Shah covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Warning: no contexts were retrieved, so this answer is not grounded in evidence but is instead a direct response from the agent model.

No citable contexts were retrieved in this run (Paper Count=0; Context IDs=[]). The system therefore cannot generate or submit the requested EDN3/EDNRB Waardenburg–Shah disease-characteristics report with PMID-level citations, URLs, publication dates, and abstract quotes under the evidence-grounding requirement.

Artifacts